Author

Fernanda Costas Casal de Faria

The Ohio State University Wexner Medical CenterORCID 0000-0002-4112-4953Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Raphael E. PollockiD· 2 shared Valerie Patrice GrignoliD· 2 shared Abeba ZewduiD· 1 shared Ali F. UsmaniiD· 1 shared Connor P Harper· 1 shared Danielle BraggioiD· 1 shared David Koller· 1 shared David WangiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Raphael E. PollockORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Extracellular vesicle-mediated suppression of macrophage STING signaling promotes immune dysfunction in dedifferentiated liposarcoma

Qi Zhang, Jay K. Mandula, Patricia Sarchet, Priya Dhawale, Fernanda Costas Casal de Faria, Timothy Zhang, Sydney Rentsch, Premanshu K. Singh, Ali F. Usmani, Roma Karna, Connor P Harper, Valerie Patrice Grignol, Jing Wang, Yong Zhang, Zihai Li, , Federica Calore

This study shows that extracellular vesicles from dedifferentiated liposarcoma suppress macrophage STING signaling, leading to immune dysfunction and poor response to immunotherapy.

bioRxiv · Aug 10, 2026 · PreprintCancer Biology

Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing

Abeba Zewdu, Danielle Braggio, Gonzalo Lopez, Kara Batte, Safiya Khurshid, Fernanda Costas Casal de Faria, Hemant Kumar Bid, David Koller, Lucia Casadei, Katherine J. Ladner, David Wang, Valerie Patrice Grignol, Obiajulu Hans Iwenofu, Dawn S. Chandler, Denis C. Guttridge D, Raphael E. Pollock

This study shows that blocking IL-6 signaling in DDLPS reduces MDM2 oncogenicity through alternative splicing, suggesting a potential therapeutic target.

PLoS ONE · Sep 17, 2025Peer-reviewedMolecular Biology